RTP-026, A POTENTIAL FIRST-IN-CLASS CARDIOPROTECTANT, SHOWS STRONG SAFETY AND PROMISING EFFICACY SIGNALS IN A PHASE 2a STUDY IN PATIENTS WITH SEVERE HEART ATTACK
ResoTher Pharma announces encouraging top-line results from its Phase 2a clinical study [...]
CFO of two companies chooses sides: “Challenging to make time add up”
“A completely new and very exciting funding opportunity,” combined with a passion [...]
ResoTher Pharma initiates dosing in its Phase 2a clinical trial in myocardial infarction patients
ResoTher Pharma is pleased to announce that the first patient has been [...]
ResoTher Pharma: Improving Cardiovascular Outcomes
Please read our biography published in Life Sciences Review 'Company of the [...]
ResoTher Pharma receives a €2.5 million grant from the European Innovation Council
ResoTher Pharma, a biotech company focused on developing life-saving options for [...]
ResoTher Pharma appoints Anders Kronborg as Chief Executive Officer
Resother Pharma A/S (“ResoTher”) today announced the appointment of Anders Kronborg, as [...]
RTP-026, A POTENTIAL FIRST-IN-CLASS CARDIOPROTECTANT, SHOWS STRONG SAFETY AND PROMISING EFFICACY SIGNALS IN A PHASE 2a STUDY IN PATIENTS WITH SEVERE HEART ATTACK
ResoTher Pharma announces encouraging top-line results from its Phase 2a [...]
CFO of two companies chooses sides: “Challenging to make time add up”
“A completely new and very exciting funding opportunity,” combined with [...]
ResoTher Pharma initiates dosing in its Phase 2a clinical trial in myocardial infarction patients
ResoTher Pharma is pleased to announce that the first patient [...]
ResoTher Pharma: Improving Cardiovascular Outcomes
Please read our biography published in Life Sciences Review 'Company [...]
ResoTher Pharma receives a €2.5 million grant from the European Innovation Council
ResoTher Pharma, a biotech company focused on developing life-saving [...]
ResoTher Pharma appoints Anders Kronborg as Chief Executive Officer
Resother Pharma A/S (“ResoTher”) today announced the appointment of Anders [...]
